No Residual Activity of Raltegravir After Development of 148 Complex Mutations In Vivo

Kempf DJ , Isaacson JD , King MS , et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol. 2001;75: 7462-7469.

Steigbigel RT , Cooper DA , Kumar PN , et al, and BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339-354.

Cooper DA , Steigbigel RT , Gatell JM , et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355-65.

Iwamoto M. , Wenning LA , Mistry GC , et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis. 2008;47:137-140.

Acosta EP , Henry K. , Baken L. , Page LM , Fletcher CV Indinavir concentrations and antiviral effect. Pharmacotherapy . 1999;19:708-712.